Search Results for Trastuzumab

Showing 1 – 4

NICE, Roche Reach Deal on Breast Cancer Drug By Michael Mezher - Published 15 June 2017

Patients in the UK could soon get access to Roche's targeted breast cancer drug Kadcyla (trastuzumab emtansine) through the National Health Service (NHS) as early as next month, the National Institute for Health and Care Excellence (NICE) said on Thursday.

Categories: News, Europe, NICE, Biologics and biotechnology, Reimbursement

Tags: NICE, Roche, Kadcyla, Herceptin, Trastuzumab

WHO to Begin Cancer Biosimilar Prequalification Pilot This Fall By Michael Mezher - Published 04 May 2017

The World Health Organization (WHO) on Thursday announced it will invite biosimilar makers to participate in a pilot program to prequalify biosimilars of two top selling biologics this September in an effort bring lower cost versions of the products to low- and middle-income countries.

Categories: News, WHO, Biologics and biotechnology, Submission and registration

Tags: Biosimilars, Prequalification, Rituxan, Herceptin, Rituximab, Trastuzumab

UK: NICE Says No to Two Breast Cancer Drugs By Louise Zornoza, RegLink - Published 28 June 2012

Categories: Regulatory Update, NICE

Tags: GlaxoSmithkline, Herceptin, lapatinib, trastuzumab, Tyverb, Breast Cancer, Roche, UK

UK: Two Breast Cancer Drugs not Recommended by NICE in Latest Draft Guidance By Louise Zornoza, RegLink - Published 27 April 2012

Categories: Regulatory Update, EMA, NICE

Tags: GlaxoSmithkline, Herceptin, lapatinib, trastuzumab, Tyverb, Cost Effectiveness, MBC, HER2, Breast Cancer, GSK, Roche, cost, UK, cancer